Lesinurad information

Lesinurad
Clinical data
Pronunciation	/lɛˈsɪnjuːræd/; le-SIN-ew-rad
Trade names	Zurampic
AHFS/Drugs.com	Monograph
MedlinePlus	a616015
License data	EU EMA: by INN; US DailyMed: Lesinurad;
Routes of; administration	Oral (tablets)
ATC code	M04AB05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	~100%
Protein binding	>98%
Metabolism	Hepatic (CYP2C9)
Elimination half-life	~5 hours
Excretion	Urine (63%), feces (32%)
Identifiers
	IUPAC name 2-{[5-Bromo-4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid;
CAS Number	878672-00-5;
PubChem CID	56928182;
DrugBank	DB11560;
ChemSpider	28527877;
UNII	09ERP08I3W;
KEGG	D09921;
ChEBI	CHEBI:90929 ;
CompTox Dashboard (EPA)	DTXSID201026091 ;
ECHA InfoCard	100.216.089
Chemical and physical data
Formula	C17H14BrN3O2S
Molar mass	404.28 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4;
	InChI InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23); Key:FGQFOYHRJSUHMR-UHFFFAOYSA-N;

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating high blood uric acid levels associated with gout.^[2] It is recommended only as an adjuvant with either allopurinol or febuxostat when these medications are not sufficient.^[3]

It received FDA approval on 22 December 2015.^[3] The European Commission granted a marketing authorisation valid throughout the European Union on 18 February 2016.^[4] In February 2019, lesinurad was discontinued in the United States by its manufacturer for business reasons, and was subsequently withdrawn in Europe in July 2020.^[5]^[6]

^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ ^a ^b "Zurampic (lesinurad) Tablets, for Oral Use. Full Prescribing Information" (PDF). AstraZeneca AB, S-151 85 Sodertalje, Sweden. Archived from the original (PDF) on 24 December 2015. Retrieved 23 December 2015.
^ ^a ^b "Drug Trial Snapshot: Zurampic". US Food and Drug Administration. 22 December 2015. Retrieved 14 October 2018.
^ "EPAR summary for the public" (PDF). EMA. 13 March 2016.
^ "Duzallo and Zurampic". Ironwood Pharmaceuticals. Archived from the original on 10 August 2020. Retrieved 31 July 2020.
^ "Duzallo". European Medicines Agency. The European Union. 17 September 2018. Retrieved 2 October 2020.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[PI-2] "Zurampic (lesinurad) Tablets, for Oral Use. Full Prescribing Information" (PDF). AstraZeneca AB, S-151 85 Sodertalje, Sweden. Archived from the original (PDF) on 24 December 2015. Retrieved 23 December 2015.

[zurampic-3] "Drug Trial Snapshot: Zurampic". US Food and Drug Administration. 22 December 2015. Retrieved 14 October 2018.

[4] "EPAR summary for the public" (PDF). EMA. 13 March 2016.

[5] "Duzallo and Zurampic". Ironwood Pharmaceuticals. Archived from the original on 10 August 2020. Retrieved 31 July 2020.

[6] "Duzallo". European Medicines Agency. The European Union. 17 September 2018. Retrieved 2 October 2020.

Lesinurad information

and 6 Related for: Lesinurad information

Lesinurad

ATC code M04

Gout

Allopurinol

Hyperuricemia

SLC22A12

Clinical data


Pronunciation	/lɛˈsɪnjuːræd/ le-SIN-ew-rad
Trade names	Zurampic
AHFS/Drugs.com	Monograph
MedlinePlus	a616015
License data	EU EMA: by INN US DailyMed: Lesinurad
Routes of administration	Oral (tablets)
ATC code	M04AB05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)^[1] US: ℞-only
Pharmacokinetic data
Bioavailability	~100%^[2]
Protein binding	>98%
Metabolism	Hepatic (CYP2C9)
Elimination half-life	~5 hours
Excretion	Urine (63%), feces (32%)
Identifiers
IUPAC name 2-{[5-Bromo-4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
CAS Number	878672-00-5
PubChem CID	56928182
DrugBank	DB11560
ChemSpider	28527877
UNII	09ERP08I3W
KEGG	D09921
ChEBI	CHEBI:90929^Y
CompTox Dashboard (EPA)	DTXSID201026091
ECHA InfoCard	100.216.089
Chemical and physical data
Formula	C₁₇H₁₄BrN₃O₂S
Molar mass	404.28 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4
InChI InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23) Key:FGQFOYHRJSUHMR-UHFFFAOYSA-N